Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
AACE, Aberrant, abundant, Academy, advisory, alpha, ambulatory, America, AmerisourceBergen, analyze, Analyzing, anchor, andHylenex, andin, angioedema, Ann, anniversary, Arbor, ASU, bilateral, biosimilar, block, boost, buffer, Cancun, Cardiology, cathepsin, cellulite, chargeback, Cinryze, collagen, Columbia, commensurate, conditionally, Conference, consecutive, constricted, contracture, Counsel, database, debilitating, declared, decreaseHylenex, deducting, defense, Deferral, deliverable, device, dimpled, discharged, discretion, distinct, distinction, doctor, Dupuytren, duration, Durect, Eli, environment, epithelial, error, esterase, exert, exploit, fat, fatal, fiber, fibrosclerotic, finishedHylenex, finishedHylenexrecombinant, finishesHylenexrecombinant, finishHylenexrecombinant, Fiske, flexibility, forHylenex, forHylenexrecombinant, formatted, frozen, genetic, GI, GSK, Harlan, headquartered, helical, hereditary, hereto, highest, home, HR, Hylenexrecombinant, hypertrophic, ICS, inactive, inhibitor, inHylenex, Interactive, InterMune, inthe, Intrexon, Jean, judicial, landscape, Language, lifecycle, Lily, Liu, living, lung, lysosomal, macromolecular, Madison, main, manufacturingHylenex, metastatic, Mexico, Michigan, migration, mild, mildly, moderate, modestly, nonclinical, ofHylenex, ofHylenexrecombinant, Ohio, opportunistic, orphan, owed, packageHylenexrecombinant, page, pain, pancreatic, panniculopathy, Peyronie, pharmacy, Pillsbury, Plaza, predecessor, Prestwick, prolonged, promotingHylenex, prompt, PronouncementsandPending, prophylactic, proteinase, provideHylenexrecombinant, Psychiatry, radiopaque, radiotherapy, rare, ready, reclassified, recommend, recommended, refund, reintroducedHylenex, reintroducedHylenexrecombinant, renewable, responding, reveal, Sanofi, scaffolding, scarring, Seasoned, sellHylenex, sellHylenexrecombinant, sellingHylenex, sellsHylenex, septa, serum, settled, Shaffer, short, shoulder, signaling, similarly, simplify, smooth, stable, suitable, Sutro, swelling, tagged, temporary, tension, text, theHylenexrecombinant, toHylenex, toHylenexrecombinant, undelivered, underlyingHylenexrecombinant, unexpected, unmet, upcoming, urography, user, usingHylenex, vendor, Venture, viropharma, vitro, vivo, VSOE, warehousing, wholesale, wholesaler, window, Winthrop, withdrew, withHylenex, XBRL
Removed:
accept, add, adjuvant, advanced, AL, Amphadasetm, Amphastar, andRule, anex, batch, bioscience, bovine, bull, CDER, clamp, clinician, College, combining, compounding, creating, cycle, cytostatic, cytotoxic, define, depletion, dosing, Enhanzetm, euglycemic, forin, freely, ICSI, incident, infringer, inPart, inRule, intracytoplasmic, introduce, invested, investigate, IVF, Jonathan, Lim, linked, LIQUIDtm, Measurementsbelow, media, multicenter, Nektar, observation, ofRegulation, onForm, onpage, oocyte, oppose, origin, outsourced, pathogen, pediatric, permanently, pharmacodynamic, premium, presence, presently, priced, procedure, progression, quantity, reach, realizable, RegistrationNo, rehydration, release, Repeat, replace, retained, satisfying, SeeFair, Sirion, slaughterhouse, sperm, sterility, strong, subtenant, sustained, synthetic, threatened, toxicity, transmission, underRule, vitroandin, vitrofertilization, vivoincluding
Filing tables
Filing exhibits
Related press release
HALO similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-120448 and 333-179444) and Form S-8 (Nos. 333-119969, 333-133829, 333-152914 and 333-174013) of Halozyme Therapeutics, Inc. and in the related Prospectuses of our reports dated March 9, 2012, with respect to the consolidated financial statements of Halozyme Therapeutics, Inc., and the effectiveness of internal control over financial reporting of Halozyme Therapeutics, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2011.
/s/ Ernst & Young LLP
San Diego, California
March 9, 2012